Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
| Autor: | Toby M. Maher |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Placebo-controlled study Disease Treatment failure Idiopathic pulmonary fibrosis Th2 Cells Transforming Growth Factor beta Pulmonary fibrosis medicine Humans Treatment Failure Intensive care medicine Proteinase Activated Receptor 1 Clinical Trials as Topic Interleukin-13 business.industry Connective Tissue Growth Factor NADPH Oxidases respiratory system medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases Clinical trial Oxidative Stress Acute Disease Immunology Cytokines Eicosanoids business Protein Kinases Progressive disease Signal Transduction |
| Zdroj: | Clinics in Chest Medicine. 33:69-83 |
| ISSN: | 0272-5231 |
| DOI: | 10.1016/j.ccm.2011.11.002 |
| Popis: | Idiopathic pulmonary fibrosis (IPF) is a progressive disease of unknown cause that conveys a dismal prognosis. In the United States there are currently no licensed therapies for treatment of IPF. The development of effective IPF clinical trials networks across the United States and Europe, however, has led to key developments in the treatment of IPF. Advances in understanding of the pathogenetic processes involved in the development of pulmonary fibrosis have led to novel therapeutic targets. These developments offer hope that there may, in the near future, be therapeutic options available for treatment of this devastating disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|